As per reports, the European Medicines Agency has issued warnings against the use of ivermectin, Merck & Co’s (MRK) anti-parasite drug for the prevention or treatment of COVID-19 outside clinical trials.
A similar warning was also issued from the U.S. Food and Drugs Administration stating, as per the analysis of available data, the study does not support the safety and efficacy of the drug for COVID-19 treatment. The EMA informed that drugs can block the replication of the virus but at much higher drug dosages.
“Although ivermectin is generally well tolerated at doses authorized for other indications, side effects could increase with the much higher doses than would be needed to obtain concentrations of ivermectin in the lungs that are effective against the virus,” stated the EMA.
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.
